Overview
3-methylglutaconic aciduria with neonatal cataract, neurologic involvement, and congenital neutropenia syndrome (sometimes called MGCA type 9 or CLPB-related disorder) is a very rare inherited metabolic disease that affects multiple body systems from birth or early infancy. It is caused by changes (mutations) in the CLPB gene, which provides instructions for making a protein that helps cells manage stress and maintain healthy mitochondria — the energy-producing parts of cells. The condition causes a buildup of a chemical called 3-methylglutaconic acid in the urine, which is a key clue for diagnosis. Children with this syndrome are typically born with cloudy lenses in their eyes (cataracts), have a low number of infection-fighting white blood cells (neutropenia), and show signs of nervous system problems such as movement difficulties, intellectual disability, and sometimes seizures. The combination of these features — eye, blood, and brain involvement — is what makes this syndrome distinct. There is currently no cure. Treatment focuses on managing each symptom: surgery for cataracts, medications or growth factors to boost white blood cell counts and prevent infections, and therapies to support development and neurological health. Early diagnosis is important so that complications like serious infections can be prevented and developmental support can begin as soon as possible.
Also known as:
Key symptoms:
Cloudy lenses in both eyes (cataracts) present at birthVery low white blood cell count (neutropenia), increasing risk of serious infectionsBuildup of 3-methylglutaconic acid detected in urineIntellectual disability or developmental delayMovement problems such as poor coordination or abnormal muscle toneSeizuresFeeding difficulties in infancyFailure to thrive or poor weight gainRecurrent or severe bacterial infections due to low white blood cellsBrain abnormalities visible on MRI scans
Clinical phenotype terms (38)— hover any for plain English
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Neonatal
Begins at or shortly after birth (first 4 weeks)
Treatments
No FDA-approved treatments are currently listed for 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome.
Community
No community posts yet. Be the first to share your experience with 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome.
Start the conversation →Latest news about 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome
No recent news articles for 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What is the current severity of my child's neutropenia, and what infection warning signs should send us to the emergency room immediately?,Should my child start G-CSF treatment, and how will we monitor whether it is working?,How soon should cataract surgery be done, and what vision outcomes can we realistically expect?,What developmental therapies do you recommend starting right away, and how do we access them?,Are there any clinical trials or research studies we should consider enrolling in?,What does the brain MRI show, and how does it relate to my child's developmental outlook?,What is the recurrence risk for future pregnancies, and is genetic counseling available for our family?
Common questions about 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome
What is 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome?
3-methylglutaconic aciduria with neonatal cataract, neurologic involvement, and congenital neutropenia syndrome (sometimes called MGCA type 9 or CLPB-related disorder) is a very rare inherited metabolic disease that affects multiple body systems from birth or early infancy. It is caused by changes (mutations) in the CLPB gene, which provides instructions for making a protein that helps cells manage stress and maintain healthy mitochondria — the energy-producing parts of cells. The condition causes a buildup of a chemical called 3-methylglutaconic acid in the urine, which is a key clue for dia
How is 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome inherited?
3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.
At what age does 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome typically begin?
Typical onset of 3-methylglutaconic aciduria-neonatal cataract-neurologic involvement-congenital neutropenia syndrome is neonatal. Age of onset can vary across affected individuals.